CBM:NYE-Cambrex Corporation (USD)

COMMON STOCK | Other | NYE

Last Closing Price

USD 59.99

Change

0.00 (0.00)%

Market Cap

USD 2.02B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BMS Bemis Company, Inc

N/A

USD370,676,430.93B 1,000,000.00 N/A
NAO Nordic American Offshore Ltd

N/A

USD387,070.41B N/A N/A
ITC ITC Holdings Corp

N/A

USD3,166.52B 22.84 N/A
USB-PA U.S. Bancorp PERP PFD SER A

N/A

USD1,524.48B 206.60 N/A
MSF Morgan Stanley Emerging Market..

N/A

USD1,000.65B 24.60 N/A
HSBC-PA HSBC Holdings plc ADR A 1/40PF..

+0.05 (+0.19%)

USD543.00B 1,677.50 N/A
SAN-PB Banco Santander, S.A. GTD PFD ..

-0.02 (-0.08%)

USD384.51B 46.00 N/A
BAC-PW Bank of America Corporation

N/A

USD267.69B 9.46 N/A
BAC-PY Bank of America Corporation

N/A

USD263.53B 9.36 N/A
BEL Belmond Ltd

N/A

USD261.58B 15.94 N/A

ETFs Containing CBM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 0.15% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.15% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 11.86% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.86% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.42% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.42% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.18% N/A N/A N/A N/A
Risk Adjusted Return 40.64% N/A N/A N/A N/A
Market Capitalization 2.02B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 56.59 N/A N/A N/A N/A
Price/Book Ratio 2.99 N/A N/A N/A N/A
Price / Cash Flow Ratio 23.26 N/A N/A N/A N/A
EV/EBITDA 15.20 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 12.82% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 45.89% N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.16 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike